Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma

Teru Hideshima(Dana-Farber Cancer Institute), K C Anderson(Harvard University)

Blood Cancer Journal

May 15, 2015

10.1038/bcj.2015.38

Cited by 64

Related Papers

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

|Proceedings of the National Academy of Sciences|2005|596

Advances in biology of multiple myeloma: clinical applications

|Blood|2004|583

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

|Blood|2003|569

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

|Blood|2006|421

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications

|Blood|2009|73